Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Summary

The goal of this clinical trial is to investigate the safety and feasibility of neoadjuvant immunotherapy for patients with high-risk uveal melanoma. The main question is: \- Is neoadjuvant treatment with nivolumab and ipilimumab safe and feasible for patientt with high-riks uveal melanoma? In addition pathological response, distant metastases-free survival, overall survival and immunological changes in the tumor microenviroenment after therapy will be assesed.

Timeline

Start

2026-06-29

Primary completion

2029-06-01

Completion

2029-06-01

Drugs

Indications